Inclusion Criteria:

          -  Age 18 years or older

          -  Histologically or cytologically confirmed pancreatic adenocarcinoma. Must have locally
             advanced, recurrent, or metastatic disease ineligible for curative intent treatment(s)
             and eligible for first line systemic treatment.

          -  Must have radiologic imaging with a computed tomography (CT) scan or magnetic
             resonance imaging (MRI) within 22 days of study entry

          -  Must have at least one measurable lesion according to RECIST 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Adequate gastrointestinal (GI), bone marrow, liver and kidney function

          -  Life expectancy minimum of > 12 weeks

          -  Adequate recovery from surgery to Grade 1 or baseline with at least 28 days from time
             of major surgery

        Exclusion Criteria:

          -  Received last dose of chemotherapy (neoadjuvant or adjuvant), surgery, or radiation
             treatment with curative intent within 6 months prior to study entry

          -  Islet-cell neoplasms

          -  Prior malignancy within the past 3 years except adequately treated basal or squamous
             cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate,
             cervix or breast

          -  Symptomatic uncontrolled central nervous system (CNS) metastasis or brain metastases
             unless adequately treated and controlled

          -  Evidence of clinically significant third spacing (e.g. pleural effusion, ascites,
             anasarca, etc.) within 28 days prior to study entry

          -  Serious active infection requiring IV antibiotics and/or hospitalization at study
             entry

          -  Active human immune deficiency (HIV) syndrome, hepatitis B, hepatitis C, or other
             active viral illness